Hormone replacement therapy and patterns of osteoarthritis: baseline data from the Ulm Osteoarthritis Study

Andrea Erb, Hermann Brenner, Klaus-Peter Günther, Til Stürmer

Abstract

Objectives—It has been suggested that hormone replacement therapy (HRT) may protect against osteoarthritis (OA). The aim of this paper was to assess the association between HRT and radiographically defined patterns of OA.

Methods—175 consecutive women aged 50 years or older (mean age 66.1) who underwent hip or knee joint replacement because of advanced OA in four hospitals in south west Germany were enrolled in a cross sectional study. Participants underwent a standardised interview including detailed history of medication use and a physical examination. Furthermore, radiographs of the joint being replaced and of the contralateral joint as well as of both hands were obtained. Patients were categorised as having bilateral or unilateral OA according to the presence or absence of radiographic OA in the contralateral joint. If radiographic OA of different hand and finger joint groups was present, participants were categorised as having generalised OA (GOA). Logistic regression was used to estimate odds ratios and their 95% confidence intervals for the association between HRT and bilateral or GOA while adjusting for potential confounders.

Results—Fifty five women (11.6%) were using HRT. The median duration of use was 5.4 years. The prevalence of bilateral and GOA was similar among users of ORT (86.3% and 27.5%, respectively) and among non-users of HRT (88.7% and 35.7%, respectively). After adjustment for potential confounding factors, the odds ratios (95% confidence intervals) of bilateral OA and GOA among HRT users compared with non-users was 1.21 (0.48, 3.03) and 1.21 (0.53, 2.74), respectively.

Conclusion—Despite limited generalisability because of the selective study sample, these data do not support the hypothesis that HRT acts as a systemic protective factor against OA.


Osteoarthritis (OA) is the most common joint disorder and a major cause of disability in elderly people. Treatment options of OA are limited and concentrate on the relief of symptoms or joint replacement.

The use of hormone replacement therapy (HRT) after menopause has increased in recent years because of its beneficial effects on menopausal symptoms, bone mineral density and cardiovascular disease.

Sex hormones are likely to play a part in the development of OA in women. Before age 50, incidence of OA is much lower among women than among men. By contrast, the increase in incidence above age 50 is much steeper among women than among men. This suggests that the female oestrogen loss after menopause might be a risk factor for OA development. As HRT reduces various sequelae of oestrogen loss after menopause, it may protect against OA. On the other hand, HRT prevents bone loss after menopause, and a higher bone density was found to be prevalent in women with OA. According to the latter theory, HRT may be an indirect risk factor for OA.

Recent cross sectional studies have found an inverse association between ORT use and the prevalence of hip OA and knee OA. Hannan et al found a modest, but non-significant inverse association between oestrogen use and prevalence of knee OA in the Framingham study. A recent eight year follow up of the Framingham cohort as well as a four year follow up of the Chingford study indicated that current use of HRT had a moderate, but statistically non-significant protective effect against incident knee OA. In contrast, a nested case-control study could not confirm an association between current HRT use and the incidence of hip, knee and hand OA. However, a high OA incidence was found in new oestrogen users and the authors concluded that the utilisation of medical services by new HRT users increases the likelihood of an OA diagnosis. Concerning hand OA, no association with HRT use was observed in two cross sectional studies.

The aim of this study was to assess the relation between HRT and radiographically defined patterns of OA in a large sample of post-menopausal women participating in the Ulm Osteoarthritis Study.

Methods

STUDY DESIGN AND POPULATION
The main reason for data regarding the epidemiology of OA being sparse compared with other diseases with major public health impact is the difficulty of performing invasive diagnostics such as radiology in population samples (cross sectional or cohort studies) or healthy people (case-control studies). This difficulty can be circumvented to some degree if different OA patterns are studied among patients with

Department of Epidemiology, University of Ulm, Germany, Helmholtzstr 22, D-89081 Ulm, Germany
A Erb
H Brenner
T Stürmer

Department of Orthopaedic Surgery, University of Ulm, K-P Günther

Correspondence to: Dr Erb

Accepted for publication 5 November 1999

Department of Epidemiology, University of Ulm, Germany, Helmholtzstr 22, D-89081 Ulm, Germany
A Erb
H Brenner
T Stürmer

Department of Orthopaedic Surgery, University of Ulm, K-P Günther

Correspondence to: Dr Erb

Accepted for publication 5 November 1999
joint replacement because of OA. These patients are in close surveillance and radiographs of additional joints (contralateral hip or knee, hands) can more easily be obtained. Although this design does not permit comparison of persons with and without OA; comparisons of subgroups of people with unilateral or bilateral OA and localised or generalised OA (GOA) are possible and might provide clues as to the potential role of systemic risk factors in the disease process.

Following these considerations, the Ulm Osteoarthritis Study enrolled consecutive patients who were hospitalised for hip or knee joint replacement because of advanced OA. Details of the study design have been reported elsewhere.11 Briefly, four orthopaedic centres in south west Germany participated in the study. Between January 1995 and December 1996, 1037 patients under the age of 76 were eligible for recruitment. Among these, 212 (20%) were operated on before they could be examined and 16 (1.5%) refused to participate. After written informed consent, 809 patients were recruited in the study, of whom 504 were women. We were unable to assess menopausal status in 147 women with hysterectomy, because these women usually gave their age at surgery as menopausal age. As we felt potential bias by exclusion of these women to be more important than potential bias by excluding a few women with early menopause and including a few women with unknown menopausal status, we included all 475 women aged 50 years (mean age at menopause for women without hysterectomy) or more with available information on medication use in our current analysis.

DATA COLLECTION
Patients were interviewed and examined by trained physicians on the day before the joint replacement according to a standardised protocol. Information about age, height and weight, history of diabetes and gout, history of surgery, current or past cigarette smoking, age at menopause and number of full term pregnancies was obtained.

HRT
The interview also included a detailed history of regular medication use during the past three months, including hormone preparations. Drug use and brand names were verified, if possible, by inspection of medication packages brought to the hospital. To estimate the duration of use, the starting date of the medication was asked for.

Up to three active ingredients for up to 15 preparations were classified according to the ATC classification (WHO Collaborating Centre for Drug Statistics Methodology, Oslo, 1993). HRT use was defined as regular use of any drug containing postmenopausal oestrogens in the past three months. HRT was furthermore classified according to whether progesteron was administered together with oestrogen or not. Analyses were confined to oral, transdermal and intramuscular applications. Topical oestrogens or vaginal suppositories were not considered because their systemic effects are expected to be negligible.

Radiographic assessment of OA
Standard radiographs were taken for the joint being replaced, the contralateral joint and both hands. Patients with hip OA underwent a radiographic examination consisting of a supine anteroposterior pelvic view, while patients with knee OA had anteroposterior weight bearing and lateral non-weight bearing radiographs of both knees. All hip and knee radiographs were read by one trained senior orthopaedic surgeon (KPG) without further information about the patient. Hip or knee OA was classified according to the Kellgren and Lawrence score from grade 0 (no OA) to 4 (advanced OA) using a standard reference atlas.12 Grade 0 and 1 were considered as normal, whereas grade 2 or higher was defined to represent manifest OA. The reliability of radiographic grading of OA according to the Kellgren and Lawrence score on the hip and knee joints was assessed in 100 radiographs and was found to be high (inter-rater agreement between multiple orthopaedic surgeons: intraclass correlation coefficient (ICC)=0.88 for hip OA and 0.81 for knee OA; intra-rater agreement for the rater of this study: ICC=0.88 for hip OA and 0.93 for knee OA). All patients had OA of the replaced joint. If OA was also present in the joint contralateral to the one being replaced, the patient was classified having a bilateral OA.

Hand radiographs were read by another trained orthopaedic surgeon without further information about the patient. All visible finger joints (proximal interphalangeal, PIP, and distal interphalangeal, DIP) and the carpometacarpal joints (CMC) were evaluated regarding osteophytes, joint space narrowing and subchondral sclerosis. A definite joint space narrowing or possible joint space narrowing in combination with definite osteophytes and/or subchondral sclerosis were considered as OA. This score puts more weight on joint space narrowing than on osteophytes, because osteophytes are often absent in finger joints despite joint space narrowing and sclerosis, and because joint space narrowing has been shown to have better reproducibility than osteophytes.13 14 If OA was found in two or more finger joints and in one or both CMC joints in addition to OA of the replaced joint, the patient was considered to have GOA.11 15 The reliability of this classification was assessed in 50 pairs of hand radiographs and was found to be sufficiently good (inter-rater agreement: k=0.73; intra-rater agreement for the rater of this study: k=0.54).

STATISTICAL ANALYSES
We first carried out descriptive analyses on basic sociodemographic variables, HRT use, and the prevalence of bilateral OA and GOA in the study population. We assessed the difference in the prevalence of possible confounding factors between HRT users and non-users and its large sample 95% confidence interval. We then compared the prevalence of bilateral OA and GOA between users and non-users of HRT using multivariable logistic regression to adjust the association between HRT use and...
Hormone replacement therapy and patterns of osteoarthritis

Women using HRT had a slightly lower prevalence of bilateral OA (86.3%) than women not using HRT (88.7%). This was mainly attributable to confounding by age, however. After adjustment for age and the other covariates, there was a weak, statistically non-significant positive association between oestrogen use and bilateral OA (OR=1.21; 95% CI: 0.48, 3.03).

Users of HRT had a somewhat lower prevalence of GOA (27.5%) compared with non-users (35.7%) resulting in a crude odds ratio of 0.68 (95%CI:0.33, 1.42). Again, the crude odds ratio was strongly confounded by age. After adjustment for confounding, there was a weak, statistically non-significant positive association between HRT and GOA (OR=1.21; 95% CI: 0.53, 2.74).

Conducting the analysis according to the duration of current oestrogen use, we found no major differences in the prevalences of generalised or bilateral OA between women who used HRT five years or more, less than five years, and non-users (table 4), but the small numbers in the subgroups have to be taken into account. Looking at women with use of oestrogen mono-preparations and oestrogen-gestagen combinations separately, we found no significant differences between either of the two subgroups in comparison with non-users concerning both bilateral and GOA (data not shown).

### Results

The mean age of the study participants was 66.1 years. Overall, 55 of 475 women were using HRT (table 1). Of these, 29 were taking oestrogen only preparations and 26 used oestrogen-gestagen combinations. The median duration of use was 5.4 years with an interquartile range from 2.3 to 8 years. One hundred and ninety four women had prevalent hip OA, and 281 women had prevalent knee OA. Radiographs of the contralateral joint were available for 91% of the women (9% refused additional radiographs of the contralateral joint), and a bilateral hip or knee joint OA was observed in the majority of these patients (88.2%). For 79% of the women, radiographs of the hands were available (missing values attributable to patients refusing additional hand radiographs) and 34.7% of these had a GOA.

Table 2 shows the distribution of potential confounding variables according to the use of HRT. Looking at the median age, HRT users were seven years younger than non-users of HRT. Women with oestrogen intake were less likely to have diabetes and more likely to be current smokers and having had a hysterectomy. There were no major differences between the groups regarding body mass index, age at menopause, gout and thiazide use.

In table 3 we present the number of participants and the prevalence of bilateral and GOA according to oestrogen intake, followed by the crude and adjusted odds ratios (OR) and their 95% confidence intervals (CI) for the association between HRT use and the different OA patterns. Odds ratios above one correspond to a higher prevalence of bilateral or GOA in HRT users compared with non-users.

### Discussion

In contrast with previous studies reporting a protective effect of HRT on knee or hip OA, we observed no association between HRT use and either bilateral knee or hip OA or GOA in the Ulm Osteoarthritis Study.

Two recent cross sectional studies found an inverse association between HRT and prevalent hip or knee OA. In the Chingford Study, 45–64 year old women examined current users of HRT for more than one year showed a one third lower prevalence of radiographically defined knee OA, which was defined by osteophytes, than non-users (OR=0.31; 95% CI: 0.11, 0.93). In the Study of Osteoporotic Fractures' participants 65 years or older were included. An inverse association of HRT use with hip OA, which was defined on a radiographic summary score, was observed (OR=0.63; 95% CI: 0.49, 0.86). In 600 women aged 63 or older from the Framingham OA Study, women who ever used HRT for more than two years showed a one third lower prevalence of radiographically defined knee OA, but the difference from non-users was statistically non-significant. This inverse association was stronger looking at women with bilateral OA only (OR=0.52; 95% CI: 0.25, 1.09). In contrast with the cross sectional studies, the exposure in the Framingham Study was assessed before the outcome making a bias of reversed causality less likely.

Two recent population based prospective studies also suggested a moderate protective effect of HRT regarding the incidence of knee OA, but the confidence intervals around these estimates were wide and included the null value. In an eight year follow up of the Framingham cohort, a possible reduction of

### Table 1 Description of the study population

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Number</th>
<th>(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>475</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>66.1</td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>67</td>
<td></td>
</tr>
<tr>
<td>Interquartile range</td>
<td>62–71</td>
<td></td>
</tr>
<tr>
<td>HRT users</td>
<td>55 (11.6%)</td>
<td></td>
</tr>
<tr>
<td>Oestrogen mono-therapy</td>
<td>29 (52.7%)</td>
<td></td>
</tr>
<tr>
<td>Oestrogen-gestagen combinations</td>
<td>26 (47.3%)</td>
<td></td>
</tr>
<tr>
<td>Hip OA</td>
<td>194 (40.8%)</td>
<td></td>
</tr>
<tr>
<td>Knee OA</td>
<td>281 (59.2%)</td>
<td></td>
</tr>
<tr>
<td>Bilateral OA*</td>
<td>382 (88.2%)</td>
<td></td>
</tr>
<tr>
<td>Hand radiographs</td>
<td>376 (79.2%)</td>
<td></td>
</tr>
<tr>
<td>Generalised OA†</td>
<td>131 (27.4%)</td>
<td></td>
</tr>
</tbody>
</table>

*Defined as radiological OA (Kellgren and Lawrence score ≥2) of replaced joint and contralateral joint. †Defined as radiological OA (Kellgren and Lawrence score ≥2) of at least two finger joints and ≥1 carpometacarpal joint in addition to uni- or bilateral OA of hip or knee.

### Table 2 Distribution of potential confounding variables according to the use of hormone replacement therapy

<table>
<thead>
<tr>
<th>Variable</th>
<th>HRT users</th>
<th>Non-users</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>66.1</td>
<td>66.8</td>
<td>0.17</td>
</tr>
<tr>
<td>Body mass index (BMI)</td>
<td>28.3</td>
<td>28.2</td>
<td>0.73</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>2.3</td>
<td>3.4</td>
<td>0.03</td>
</tr>
<tr>
<td>Current smokers</td>
<td>1.6</td>
<td>2.0</td>
<td>0.12</td>
</tr>
<tr>
<td>Hysterectomy</td>
<td>52.7</td>
<td>52.7</td>
<td>1.00</td>
</tr>
<tr>
<td>Duration of current oestrogen use</td>
<td>5.4</td>
<td>5.6</td>
<td>0.84</td>
</tr>
</tbody>
</table>

After adjustment for confounding, there was a weak, statistically non-significant positive association between HRT and GOA (OR=1.21; 95% CI: 0.53, 2.74).

Conducting the analysis according to the duration of current oestrogen use, we found no major differences in the prevalences of generalised or bilateral OA between women who used HRT five years or more, less than five years, and non-users (table 4), but the small numbers in the subgroups have to be taken into account. Looking at women with use of oestrogen mono-preparations and oestrogen-gestagen combinations separately, we found no significant differences between either of the two subgroups in comparison with non-users concerning both bilateral and GOA (data not shown).
risk of incident radiographically defined knee OA was found in current HRT users (OR=0.4; 95% CI: 0.1, 3.0). A four year follow up of the Chingford population was compatible with a protective effect of current HRT use on the development of knee osteophytes (OR=0.4: 95% CI 0.1, 1.4), but also with an increase in risk regarding the development of joint space narrowing (OR=1.9; 95% CI: 0.9, 4.1).

HRT use was not associated with hand OA in the Chingford study. In this study, DIP and CMC OA were defined according to the Kellgren and Lawrence score and considered separately. Samanta et al observed no association between HRT and prevalent GOA, defined by Herberden’s nodes and polyarticular interphalangeal OA, in a British case-control study.

A recent case-control study did not find an association between current HRT use and incident cases of hip, knee and hand OA, which was defined as radiographic OA according to the Kellgren and Lawrence score plus symptoms. However, a high OA incidence was found in new oestrogen users, and the authors concluded that the utilisation of medical services by new HRT users increases the likelihood of an OA diagnosis. A further case-control study found a slightly positive association between women who ever used ORT for less than five years and advanced symptomatic hip OA, which might reflect a possibly higher prescription rate of oestrogens to women with present hip pain.

In the previous studies, women with OA were compared with women without OA. In contrast, participants of our study were selected according to a manifest OA of one hip or knee joint. This selection makes different access to medical care unlikely. The selection of our study participants who all had advanced OA in one hip or knee joint is likely to be independent of the different OA patterns, the laterality or generalisation. On the other hand, results of our study with participants preselected by the presence of advanced OA in at least one joint may not be generalisable to early forms or incident OA.

OA patterns in our study were classified radiographically after documentation of a very good (hip and knee joint) or sufficient (GOA) intra-rater and inter-rater reliability. Classification of the participants into patients with unilateral or bilateral OA was based on the radiograph of the joint opposite to the one being replaced. The classification into generalised or localised OA is equivalent to the definition of the Chingford study for knee OA, where GOA was defined by the presence of OA in both finger joints (DIP and PIP) and carpal-metacarpal joint in addition to knee OA.

This definition was extended to hip OA in our study, because the hip joints are—like the knee joints—big, weight bearing joints. Together with hip or knee OA, these women had radiological OA of at least three different joint groups. The overall prevalence of GOA might not be directly comparable to other studies using different radiographic gradings of hand OA, but this should not affect the validity of the internal comparisons (odds ratios) presented.

Detailed history of current medication use including hormone preparations was asked for by a trained physician and confirmed by medication packages brought to the hospital. An investigation of the Postmenopausal Estrogen/Progestin Interventions Trial showed a 95% agreement concerning the reporting of an ever

### Table 2: Distribution of possible confounding variables according to HRT

<table>
<thead>
<tr>
<th>HRT*</th>
<th>Number</th>
<th>Age</th>
<th>Interquartile range</th>
<th>BMI</th>
<th>Interquartile range</th>
<th>Age at menopause§</th>
<th>Prevalence of (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>yes</td>
<td>55</td>
<td>61</td>
<td>57–66</td>
<td>27.5</td>
<td>24.7–30.2</td>
<td>51</td>
<td>88.7% (338/381)</td>
</tr>
<tr>
<td>no</td>
<td>420</td>
<td>68</td>
<td>64–72</td>
<td>28.2</td>
<td>25.7–31.6</td>
<td>50</td>
<td>83.3 (20/24)</td>
</tr>
</tbody>
</table>

*Use of hormone replacement therapy; †Body mass index (kg/m²); ‡Based on 347 women with available information on age at menopause. §History of diabetes or use of oral antidiabetics or insulin. ¶History of gout or use of uricosurica/uricostatica.

### Table 3: Patterns of OA according to HRT

<table>
<thead>
<tr>
<th>HRT</th>
<th>Bilateral OA</th>
<th>Generalised OA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Odds ratio (95% CI)</td>
<td>Odds ratio (95% CI)</td>
</tr>
<tr>
<td></td>
<td>crude</td>
<td>adjusted*</td>
</tr>
<tr>
<td>no</td>
<td>1.00</td>
<td>(reference)</td>
</tr>
<tr>
<td>yes</td>
<td>0.80 (0.34 to 1.89)</td>
<td>1.21 (0.48 to 3.03)</td>
</tr>
</tbody>
</table>

*Adjusted for age, body mass index, diabetes mellitus, gout, thiazide intake, hysterectomy and smoking.

### Table 4: Patterns of OA according to duration of current HRT use

<table>
<thead>
<tr>
<th>Duration of HRT use</th>
<th>Bilateral OA</th>
<th>Generalised OA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Odds ratio (95% CI)</td>
<td>Odds ratio (95% CI)</td>
</tr>
<tr>
<td></td>
<td>crude</td>
<td>adjusted*</td>
</tr>
<tr>
<td>0 years</td>
<td>88.7% (338/381)</td>
<td>1 (reference)</td>
</tr>
<tr>
<td>&lt;5 years</td>
<td>83.3 (20/24)</td>
<td>0.64 (0.21 to 1.95)</td>
</tr>
<tr>
<td>5+ years</td>
<td>88.9 (24/27)</td>
<td>1.02 (0.29 to 3.52)</td>
</tr>
</tbody>
</table>

*Adjusted for age, body mass index, diabetes mellitus, gout, thiazide intake, hysterectomy and smoking.
use of HRT. As HRT use is socially well accepted it is unlikely that oestrogens are deliberately not reported in our study.

We controlled for a variety of possible confounders using multivariable logistic regression. We adjusted for age, body mass index, diabetes mellitus, gout, age of menopause, thi-azole intake, hysterectomy status and smoking. Unlike other studies we did not control for bone mineral density because this may be on the causal pathway between ORT and OA—that is, oestrogen users are less affected by loss of bone mineral density after menopause than non-users and bone mineral density might be associated with the risk of OA.

In our study, age was the main confounder of the association between HRT and different OA patterns. This results from the fact that HRT use decreases with age, while the prevalence of OA, especially GOA, is increasing.

A limitation of our study is that information was obtained for current regular medication during the past three months only. Hence, there was no information about past HRT use and the group of non-users may have included some women who have used HRT in the past. Their number should be very small, however, given that HRT use was very rare in Germany in the past. For example, in a national survey conducted eight years before our study, only 4.5% of the women between 45–80 years (mean age 58.1 years) were currently taking HRT. Therefore, possible bias attributable to missing information about past HRT use is probably small. One further possibility may be that some women stopped HRT intake before surgery because of anxiety about an increased risk of thrombosis, but it is unlikely that they stopped oestrogen medication three month before surgery, which was the time period hormone use was asked for. In current users of HRT, we had no information about the type and duration of use of different preparations in the past in case of a previous change in preparation, nor about compliance. Therefore, the results regarding duration of use have to be interpreted keeping this limitation in mind. Concerning the duration of use, a mean of a five year use might be too short to see an effect of HRT on a slowly progressive disease like OA. Furthermore, we could not investigate the time sequence between HRT and OA patterns because of the cross sectional study design. Therefore, the possibility of an OA manifestation before the beginning of HRT use cannot be ruled out. Besides, the possibility that HRT may be used by women to relief symptoms of painful joints cannot be excluded.

In summary, we did not observe an independent association between HRT and either generalised or bilateral OA in postmenopausal women with advanced OA of the hip or knee joint. Despite its limitations, our study does not support the hypothesis that HRT could act as a systemic protective factor against OA.

We would like to thank the participating institutions, Departments of Orthopaedic Surgery, (head: Dr W Puhl) and Trauma Surgery (Dr L Kanz) of the University of Ulm, Hessing Orthopaedic Hospital in Augsburg (Dr Th Naumann), and Baumann Orthopaedic Hospital in Stuttgart (Dr C T Trepte) for their effort in recruiting the patients and Ms B Mack for data processing. We would also like to thank Dr P Donelan for his ideas and support in developing the radiographic hand score.

Funding: the study was supported by a grant from the German Federal Ministry for Research and Technology (BMFT 01 EF040/0).

Hormone replacement therapy and patterns of osteoarthritis: baseline data from the Ulm Osteoarthritis Study
Andrea Erb, Hermann Brenner, Klaus-Peter Günther and Til Stürmer

Ann Rheum Dis 2000 59: 105-109
doi: 10.1136/ard.59.2.105

Updated information and services can be found at:
http://ard.bmj.com/content/59/2/105

These include:

References
This article cites 19 articles, 4 of which you can access for free at:
http://ard.bmj.com/content/59/2/105#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
  Degenerative joint disease (4641)
  Musculoskeletal syndromes (4951)
  Osteoarthritis (931)
  Clinical diagnostic tests (1282)
  Epidemiology (1382)
  Radiology (1113)
  Radiology (diagnostics) (750)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/